The effects of bile acid sequestrants on lipid profile and blood glucose concentrations: A systematic review and meta-analysis of randomized controlled trials

International Journal of Cardiology

Volumn 227, Issue , 2017, Pages 850-857

  Mazidi, Mohsen ^a,b   Rezaie, Peyman ^c   Karimi, Ehsan ^c   Kengne, Andre Pascal ^d,e  

^a INSTITUTE OF GENETICS AND DEVELOPMENTAL BIOLOGY   (China)

^b International College   (China)

^c MASHHAD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d SOUTH AFRICAN MEDICAL RESEARCH COUNCIL   (South Africa)

^e UNIVERSITY OF CAPE TOWN   (South Africa)

Author keywords

Bile acid sequestrants; Fasting blood glucose; Lipid profile; Meta analysis

Indexed keywords

BILE ACID SEQUESTRANT; CHOLESTEROL; COLESEVELAM; COLESTILAN; COLESTYRAMINE; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; PLACEBO; PRAVASTATIN; TRIACYLGLYCEROL; ANION EXCHANGE RESIN; BILE ACID; GLUCOSE BLOOD LEVEL;

ANALYTICAL PARAMETERS; ANTHROPOMETRY; CARDIOMETABOLIC PROFILE; CHOLESTEROL BLOOD LEVEL; DATA EXTRACTION; DATA SYNTHESIS; DRUG EFFECT; GLUCOSE BLOOD LEVEL; HUMAN; LIPID ANALYSIS; META ANALYSIS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PUBLISHING; QUANTITATIVE ANALYSIS; RANDOM EFFECTS MODEL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SENSITIVITY ANALYSIS; STATISTICAL MODEL; TRIACYLGLYCEROL BLOOD LEVEL; ANALYSIS; ANTAGONISTS AND INHIBITORS; BLOOD; FEMALE; MALE; PROSPECTIVE STUDY; TREATMENT OUTCOME;

ANION EXCHANGE RESINS; BILE ACIDS AND SALTS; BLOOD GLUCOSE; CHOLESTEROL, HDL; CHOLESTEROL, LDL; FEMALE; HUMANS; MALE; PROSPECTIVE STUDIES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 85003810989     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2016.10.011     Document Type: Review

References (52)

1. [1] Staels, B., Kuipers, F., Bile acid sequestrants and the treatment of type 2 diabetes mellitus. Drugs 67 (2007), 1383–1392.
2. [2] Davidson, M.H., Dillon, M.A., Gordon, B., Jones, P., Samuels, J., Weiss, S., et al. Colesevelam hydrochloride (cholestagel): a new, potent bile acid sequestrant associated with a low incidence of gastrointestinal side effects. Arch. Intern. Med. 159 (1999), 1893–1900.
3. [3] Lyons, D., Webster, J., Fowler, G., Petrie, J.C., Colestipol at varying dosage intervals in the treatment of moderate hypercholesterolaemia. Br. J. Clin. Pharmacol. 37 (1994), 59–62.
4. [4] Zieve, F.J., Kalin, M.F., Schwartz, S.L., Jones, M.R., Bailey, W.L., Results of the glucose-lowering effect of WelChol study (GLOWS): a randomized, double-blind, placebo-controlled pilot study evaluating the effect of colesevelam hydrochloride on glycemic control in subjects with type 2 diabetes. Clin. Ther. 29 (2007), 74–83.
5. [5] Bays, H.E., Goldberg, R.B., Truitt, K.E., Jones, M.R., Colesevelam hydrochloride therapy in patients with type 2 diabetes mellitus treated with metformin: glucose and lipid effects. Arch. Intern. Med. 168 (2008), 1975–1983.
6. [6] Fonseca, V.A., Rosenstock, J., Wang, A.C., Truitt, K.E., Jones, M.R., Colesevelam HCl improves glycemic control and reduces LDL cholesterol in patients with inadequately controlled type 2 diabetes on sulfonylurea-based therapy. Diabetes Care 31 (2008), 1479–1484.
7. [7] Goldberg, R.B., Fonseca, V.A., Truitt, K.E., Jones, M.R., Efficacy and safety of colesevelam in patients with type 2 diabetes mellitus and inadequate glycemic control receiving insulin-based therapy. Arch. Intern. Med. 168 (2008), 1531–1540.
8. [8] Beysen, C., Murphy, E.J., Deines, K., Chan, M., Tsang, E., Glass, A., et al. Effect of bile acid sequestrants on glucose metabolism, hepatic de novo lipogenesis, and cholesterol and bile acid kinetics in type 2 diabetes: a randomised controlled study. Diabetologia 55 (2012), 432–442.
9. [9] Chen, L., McNulty, J., Anderson, D., Liu, Y., Nystrom, C., Bullard, S., et al. Cholestyramine reverses hyperglycemia and enhances glucose-stimulated glucagon-like peptide 1 release in Zucker diabetic fatty rats. J. Pharmacol. Exp. Ther. 334 (2010), 164–170.
10. [10] Shang, Q., Liu, M.K., Saumoy, M., Holst, J.J., Salen, G., Xu, G., The combination of colesevelam with sitagliptin enhances glycemic control in diabetic ZDF rat model. Am. J. Physiol. Gastrointest. Liver Physiol. 302 (2012), G815–G823.
11. [11] Shang, Q., Saumoy, M., Holst, J.J., Salen, G., Xu, G., Colesevelam improves insulin resistance in a diet-induced obesity (F-DIO) rat model by increasing the release of GLP-1. Am. J. Physiol. Gastrointest. Liver Physiol. 298 (2010), G419–G424.
12. [12] Suzuki, T., Oba, K., Igari, Y., Matsumura, N., Watanabe, K., Futami-Suda, S., et al. Colestimide lowers plasma glucose levels and increases plasma glucagon-like PEPTIDE-1 (7–36) levels in patients with type 2 diabetes mellitus complicated by hypercholesterolemia. J. Nippon Med. Sch. = Nippon Ika Daigaku zasshi 74 (2007), 338–343.
13. [13] Herrema, H., Meissner, M., van Dijk, T.H., Brufau, G., Boverhof, R., Oosterveer, M.H., et al. Bile salt sequestration induces hepatic de novo lipogenesis through farnesoid X receptor- and liver X receptor alpha-controlled metabolic pathways in mice. Hepatology 51 (2010), 806–816.
14. [14] Lefebvre, P., Cariou, B., Lien, F., Kuipers, F., Staels, B., Role of bile acids and bile acid receptors in metabolic regulation. Physiol. Rev. 89 (2009), 147–191.
15. [15] Suzuki, T., Tsunoda-Kubota, M., Aoyama, J., Futami-Suda, S., Hashimoto, M., Igari, Y., et al. What characteristics at baseline are associated with the glucose-lowering effect of colestimide in patients with type 2 diabetes and hypercholesterolemia according to response to treatment?. J. Nippon Med. Sch. = Nippon Ika Daigaku zasshi 80 (2013), 211–217.
16. [16] Vilsboll, T., Holst, J.J., Knop, F.K., The spectrum of antidiabetic actions of GLP-1 in patients with diabetes. Best Pract. Res. Clin. Endocrinol. Metab. 23 (2009), 453–462.
17. [17] Moher, D., Liberati, A., Tetzlaff, J., Altman, D.G., Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann. Intern. Med. 151 (2009), 264–269 (W64).
18. [18] Phan, K., Tian, D.H., Cao, C., Black, D., Yan, T.D., Systematic review and meta-analysis: techniques and a guide for the academic surgeon. Ann. Cardiothorac. Surg. 4 (2015), 112–122.
19. [19] Higgins, J.P.T., GSe, Cochrane Handbook for Systematic Reviews of Interventions. Version 5.0.2. 2009, The Cochrane Collaboration, London.
20. [20] Higgins, J., GSTCCO, Cochrane handbook for systematic reviews, version 5.0. 2. 2009, The Cochrane Collaboration (OpenURL).
21. [21] Sahebkar, A., Effect of niacin on endothelial function: a systematic review and meta-analysis of randomized controlled trials. Vasc. Med. (Lond. Engl.) 19 (2014), 54–66.
22. [22] Hozo, S.P., Djulbegovic, B., Hozo, I., Estimating the mean and variance from the median, range, and the size of a sample. BMC Med. Res. Methodol., 5, 2005, 13.
23. [23] Mohsen Mazidi, E.K., Peyman rezaie, Ferns, Gordon A., Treatment with GLP1 receptor agonists reduce serum CRP concentrations in patients with type 2 diabetes mellitus: A systematic review and meta-analysis of randomized controlled trials. J. Diabetes Complicat., 2016.
24. [24] Sutton, A.J., Abrams, K.R., Jones, D.R., Sheldon, T.A., F S. Methods for meta-analysis in medical research. 2000, John Wiley & Sons, West Sussex, UK.
25. [25] Ferretti, G., Bacchetti, T., Sahebkar, A., Effect of statin therapy on paraoxonase-1 status: a systematic review and meta-analysis of 25 clinical trials. Prog. Lipid Res. 60 (2015), 50–73.
26. [26] Sahebkar, A., Are curcuminoids effective C-reactive protein-lowering agents in clinical practice? Evidence from a meta-analysis. Phytother. Res. 28 (2014), 633–642.
27. [27] Sahebkar, A., Serban, M.C., Mikhailidis, D.P., Toth, P.P., Muntner, P., Ursoniu, S., et al. Head-to-head comparison of statins versus fibrates in reducing plasma fibrinogen concentrations: a systematic review and meta-analysis. Pharmacol. Res. 103 (2016), 236–252.
28. [28] Duval, S., Tweedie, R., Trim and fill: a simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics 56 (2000), 455–463.
29. [29] Borenstein, M., Hedges, L., Higgins, J., Rothstein, H., Comprehensive Metaanalysis (Vers. 2). 2005, Englewood Cliffs, NJ, Biostat. Inc.
30. [30] Garg, A., Grundy, S.M., Cholestyramine therapy for dyslipidemia in non-insulin-dependent diabetes mellitus. A short-term, double-blind, crossover trial. Ann. Intern. Med. 121 (1994), 416–422.
31. [31] Smushkin, G., Sathananthan, M., Piccinini, F., Dalla Man, C., Law, J.H., Cobelli, C., et al. The effect of a bile acid sequestrant on glucose metabolism in subjects with type 2 diabetes. Diabetes 62 (2013), 1094–1101.
32. [32] Stein, E.A., Marais, A.D., Szamosi, T., Raal, F.J., Schurr, D., Urbina, E.M., et al. Colesevelam hydrochloride: efficacy and safety in pediatric subjects with heterozygous familial hypercholesterolemia. J. Pediatr. 156 (2010), 231–236 (e1–3).
33. [33] Yamakawa, T., Takano, T., Utsunomiya, H., Kadonosono, K., Okamura, A., Effect of colestimide therapy for glycemic control in type 2 diabetes mellitus with hypercholesterolemia. Endocr. J. 54 (2007), 53–58.
34. [34] Goldberg, R.B., Rosenson, R.S., Hernandez-Triana, E., Misir, S., Jones, M.R., Initial combination therapy with metformin plus colesevelam improves lipoprotein particles in patients with early type 2 diabetes mellitus. J. Clin. Lipidol. 6 (2012), 318–324.
35. [35] Rosenstock, J., Aggarwal, N., Polidori, D., Zhao, Y., Arbit, D., Usiskin, K., et al. Dose-ranging effects of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to metformin in subjects with type 2 diabetes. Diabetes Care 35 (2012), 1232–1238.
36. [36] Davidson, M.H., Rooney, M., Pollock, E., Drucker, J., Choy, Y., Effect of Colesevelam and niacin on low-density lipoprotein cholesterol and glycemic control in subjects with dyslipidemia and impaired fasting glucose. J. Clin. Lipidol. 7 (2013), 423–432.
37. [38] Yamakawa, T., Kaneko, T., Shigematu, E., Kawaguchi, J., Kadonosono, K., Morita, S., et al. Glucose-lowering effect of colestimide is associated with baseline HbA1c in type 2 diabetic patients with hypercholesterolemia. Endocr. J. 58 (2011), 185–191.
38. [39] Suzuki, T., Oba, K., Igari, Y., Watanabe, K., Matsumura, N., Futami-Suda, S., et al. Effects of bile-acid-binding resin (colestimide) on blood glucose and visceral fat in Japanese patients with type 2 diabetes mellitus and hypercholesterolemia: an open-label, randomized, case–control, crossover study. J. Diabetes Complicat. 26 (2012), 34–39.
39. [40] Kondo, K., Kadowaki, T., Colestilan monotherapy significantly improves glycaemic control and LDL cholesterol levels in patients with type 2 diabetes: a randomized double-blind placebo-controlled study. Diabetes Obes. Metab. 12 (2010), 246–251.
40. [41] McCrindle, B.W., Helden, E., Cullen-Dean, G., Conner, W.T., A randomized crossover trial of combination pharmacologic therapy in children with familial hyperlipidemia. Pediatr. Res. 51 (2002), 715–721.
41. [42] Donovan, J., Von Bergmann, K., Setchell, K., Isaacsohn, J., Pappu, A., Illingworth, D., et al. Effects of colesevelam HCl on sterol and bile acid excretion in patients with type IIa hypercholesterolemia. Dig. Dis. Sci. 50 (2005), 1232–1238.
42. [43] Rosenson, R.S., Rigby, S.P., Jones, M.R., Chou, H.S., Effect of colesevelam HCl monotherapy on lipid particles in type 2 diabetes mellitus. Cardiovasc. Drugs Ther. 28 (2014), 229–236.
43. [44] Bucher, H.C., Cook, R.J., Guyatt, G.H., Lang, J.D., Cook, D.J., Hatala, R., et al. Effects of dietary calcium supplementation on blood pressure: a meta-analysis of randomized controlled trials. JAMA 275 (1996), 1016–1022.
44. [45] Marina, A.L., Utzschneider, K.M., Wright, L.A., Montgomery, B.K., Marcovina, S.M., Kahn, S.E., Colesevelam improves oral but not intravenous glucose tolerance by a mechanism independent of insulin sensitivity and β-cell function. Diabetes Care 35 (2012), 1119–1125.
45. [46] Nwose, O.M., Jones, M.R., Atypical mechanism of glucose modulation by colesevelam in patients with type 2 diabetes. Clin. Med. Insights Endocrinol. Diabetes, 6, 2013, 75.
46. [47] Kobayashi, M., Ikegami, H., Fujisawa, T., Nojima, K., Kawabata, Y., Noso, S., et al. Prevention and treatment of obesity, insulin resistance, and diabetes by bile acid-binding resin. Diabetes 56 (2007), 239–247.
47. [48] Bays, H.E., Goldberg, R.B., The ‘forgotten’ bile acid sequestrants: is now a good time to remember?. Am. J. Ther. 14 (2007), 567–580.
48. [49] Brunetti, L., DeSantis, E.H., Patient tolerance and acceptance of colesevelam hydrochloride: focus on type-2 diabetes mellitus. Pharm. Ther. 40 (2015), 62–67.
49. [50] Potthoff, M.J., Potts, A., He, T., Duarte, J.A., Taussig, R., Mangelsdorf, D.J., et al. Colesevelam suppresses hepatic glycogenolysis by TGR5-mediated induction of GLP-1 action in DIO mice. Am. J. Physiol. Gastrointest. Liver Physiol. 304 (2013), G371–G380.
50. [51] Ross, S., D'Mello, M., Anand, S.S., Eikelboom, J., Stewart, A.F., Samani, N.J., et al. Effect of bile acid sequestrants on the risk of cardiovascular events: a Mendelian randomization analysis. Circ. Cardiovasc. Genet. 8 (2015), 618–627.
51. [52] Nuesch, E., Trelle, S., Reichenbach, S., Rutjes, A.W., Tschannen, B., Altman, D.G., et al. Small study effects in meta-analyses of osteoarthritis trials: meta-epidemiological study. BMJ (Clin. Res. Ed.), 341, 2010, c3515.
52. [53] Sterne, J.A., Gavaghan, D., Egger, M., Publication and related bias in meta-analysis: power of statistical tests and prevalence in the literature. J. Clin. Epidemiol. 53 (2000), 1119–1129.